Classification & Viability

Which regulatory category your product falls in — and whether the route you’re planning is actually open.

Q: Why pay for the opinion before building the filing?

Getting the category wrong is the most expensive mistake in the process - it sends you down a route that was never open and you find out after the money is gone. The opinion tells you, before that, whether the path you're planning exists.

Before you spend building a filing, get a written read on what your product is and which market routes its category really allows — go or no-go, in writing, from someone with no filing to sell you on the answer.

Why this matters nowThe pathway is closing

Many ingredients reach market on a self-affirmed GRAS conclusion the maker never files with FDA. In March 2025 HHS directed FDA to explore a rule to end self-affirmation, and a bill in Congress would make GRAS notice mandatory. A route you counted on may not be there in a year.

HHS directive to FDA, Mar 10 2025 · FDA GRAS rulemaking on the Unified Agenda · S. 3122 (2025), mandatory-notification bill

What this is

What your product is, and whether its route to market actually exists.

Before a label, a spec, or a dossier means anything, one question decides everything downstream: what is this product in the eyes of the rules — a drug, a supplement, a cosmetic, a food, a food additive, or a new dietary ingredient — and does the category you’re aiming for actually allow the way you plan to sell it. Get that wrong and you spend on a route that was never open. We read the product against the lines that decide its category and name the route that is genuinely there.

Classification & Viability Opinion

A written regulatory opinion on what your product is and whether its route to market holds — before you spend building the filing. Start at the base; add the evidence read when the route itself is the question.

What this covers

Product / ingredient classification — drug, supplement, cosmetic, food, food-additive, NDI
Intended-use & claims category read
Market-pathway viability — GRAS, NDI, food-additive, novel-food
Pre-dossier go / no-go feasibility
Regulatory due-diligence opinion for an investor or retailer

What you get back

A reasoned, written call you can put in front of an investor, a retailer, or your own team to decide go or no-go before you spend on a filing. It names the route we assess as open, not the one you hoped for, and it says plainly where the route you want is a dead end. Not a quick regulatory chat and not a template decision tree — a call you can act on and defend, written by someone whose fee is the same whether the answer is go or no-go. It’s built to surface the plan that reads viable but rests on a category the product doesn’t actually fall in.

What this opinion catches

A worked example — a “self-affirmed GRAS” ingredient whose safety basis describes a different material than the one in the drum.

A constructed teaching case: a functional-mushroom maker selling a bulk extract as “100% fruiting body, 30% beta-glucan,” with a self-affirmed GRAS conclusion on file. Here is what the read surfaced once the conclusion was held against the records and the route it claims — each catch tied to a real, checkable failure mode.

Specimen drawn from the True Fruit™ / Cascadia Fungi case — mycelium-on-grain sold as fruiting body

01The safety basis is written for a substance the records don’t make.

Reads as“Fruiting-body extract, self-affirmed GRAS — conclusion on file.”

Hiding in itThe batch record pools fruiting-body biomass with whole colonized grain (mycelium-on-grain), substrate left in and never separated, while the dossier characterizes only “fruiting-body extract.”

Why it mattersA GRAS conclusion has to rest on the substance you actually sell. When identity and the safety basis describe different materials, the conclusion is not defensible — and the route built on it is not open.

GRAS identity-to-substance basis

02The headline number doesn’t measure what it claims to.

Reads asA certificate showing “≥30% beta-glucan.”

Hiding in itThe figure is a non-specific total-polysaccharide measurement that counts the grain substrate’s α-glucan (starch) as if it were bioactive β-glucan. No enzymatic assay separates the two.

Why it mattersThe safe-use and viability case leans on a value that does not measure the analyte it names. The number proves nothing it implies, and a buyer’s own lab will find that.

Method does not measure the analyte claimed

03The exposure estimate counts one serving and ignores the rest.

Reads asA dietary-exposure estimate that looks complete.

Hiding in itIt counts only the coffee serving and ignores cumulative exposure across the line — capsules plus coffee — and the concentration factor of a 10:1 extract.

Why it mattersA GRAS conclusion stands on a realistic estimate of how much people actually consume. Understate the exposure and the safety margin underneath the whole route collapses.

Dietary-exposure (EDI) basis

!The pathway was self-affirmed and never filed — just as the rule that ends it is being written.

Reads as“Self-affirmed GRAS” on the trade sheet.

Hiding in itNo GRAS notice was submitted to FDA and no “no questions” letter exists — the exact self-affirmation route FDA has moved to eliminate.

Why it mattersA firm acting with foresight files a GRAS notice ahead of the rule and builds the identity and exposure basis to survive it. This one did neither — which is the difference between a route and a dead end.

Self-affirmed GRAS · no premarket notice

Build your opinion

Standardwhat the product is, and the routes its category allows

Included

What it is, and which routes are open$3,250

Reads the product against the lines that decide its legal category — drug, supplement, cosmetic, food, food-additive, or new dietary ingredient — and against the market routes that category actually allows. The written call on what you’re selling and how it can reach the market.

You send: Product / Ingredient Identity & Intended-Use StatementA description of a product or ingredient — what it is and what it is made of, how it will be used, and the claims and marketing it will carry.Also called: intended-use statement, product description, ingredient identity, product profileFull details on the Records page

Exceeding Standardsdoes the route you want actually hold

Optional add-on — tap to add

The route is actually open, not just identified+ $4,500

Knowing what your product is does not tell you the route is clear. We test your own evidence — history of use, presence in the food supply, the safety literature, any prior determinations or notifications — against the route you want, and tell you whether a GRAS basis, a genuine NDI, or EU novel-food viability is likely to hold before you build a filing on it. The difference between “this is a supplement” and “this can be sold the way you plan.”

You also send: Pathway Evidence FileThe evidence that a route to market is available and defensible — history or common use in food, presence in the food supply, published safety literature, and any prior FDA determinations or notifications — supporting a GRAS, NDI, food-additive, or novel-food pathway.Also called: GRAS evidence, history-of-use documentation, NDI evidence, novel-food evidenceFull details on the Records page

If your records can’t support a clean opinion on the route you want, you get a straight read on what stands in the way instead, at the same fee.

Your opinion$3,250base only

Common questions

Straight answers.

Isn’t this just a regulatory chat I could get for free?

A chat gives you an opinion in the moment with nothing you can hold. This is a reasoned, written call you can put in front of an investor, a retailer, or your own team and act on. It names the route that is actually open and says where the one you want isn’t — in writing.

Why pay for the opinion before building the filing?

Because getting the category wrong is one of the most expensive mistakes you can make — it sends you down a route that was never open and you find out after the money is gone. The opinion tells you, before any of that, whether the path you’re planning exists.

My ingredient is “self-affirmed GRAS” already. Am I covered?

Self-affirmation means you concluded it yourself and never filed with FDA. That route is exactly the one FDA has moved to eliminate, and a self-affirmed conclusion is only as good as the identity, exposure, and evidence under it. We tell you whether yours would hold — or build the notice that would.

Do you file the submission with FDA for me?

No. We build the submission or the roadmap to one; you file it. We don’t run the lab studies, convene the expert panel, or act as your agent with the agency — that keeps the work independent of the filing decision.

What if my records can’t support a filing yet?

You get that plainly, at the same fee, with the ordered path to get there — the specific work, data, and corrections the route needs. We don’t build a filing designed to bounce. Sometimes the honest answer is “not yet, and here’s why,” and that saves you the five figures and months a dead filing costs.

Is this legal advice?

No — it is an independent regulatory opinion or a built work product, not legal counsel, and it creates no attorney-client relationship. If your question is what your product is and whether its route to market actually exists, that is ours.

Where to go from here

The opinion is the start.

Once you know what your product is and whether its route is open, here’s where it goes next — whichever fits where you land.

Have it built · Service Premarket Safety Filing If the route needs a submission — NDI, GRAS, food-additive, or EU novel-food — we build it from your records, or the ordered path to one. See the service Implement the system · Program The compliance system for your category The moment you know what you are, the complete document system for your standard is already built — supplement, cosmetic, food, or OTC. You buy it and put it in place, at your own pace. Browse the programs

Regulatory work product, not legal advice. A deliverable is prepared from the records you submit and is not legal counsel, not a guarantee of any regulatory or market outcome, and forms no attorney-client relationship. It is prepared for your own use; any reliance by an investor, retailer, or other third party is at their own risk and creates no duty to them absent a separate written agreement. The go-to-market decision, and responsibility for your product’s compliance, remain yours. Where the records provided can’t support a defensible result, we deliver a findings report on what stands in the way instead. True Fruit™ / Cascadia Fungi Labs is a constructed teaching case; no real company or product is depicted.